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dissections is attractive in selected cases (adverse anatomy, small
vessels, type A-B dissections). However, we believe that only
properly designed studies will be able to determine whether this
strategy is superior to stenting in most patients experiencing
nonocclusive dissections. In the interim, accepting the potential
risk of vessel closure and the logistic implications (prolonged
observation or even repeat angiography) inherently associated with
the conservative strategy should be weighted against the results of
coronary stenting using currently available stent designs. Although
we sympathize with the words of caution against the indiscrimi-
nate use of stents, it would appear more reasonable to challenge
first the systematic use of “elective” stenting in clinical/
angiographic settings where its efficacy—as compared with
PTCA—remains largely unsettled.
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REPLY
Dr. Alfonso asks why two patients in our study (1) with occlusive
dissection after percutaneous transluminal coronary angioplasty
(PTCA) were excluded and when these dissections occurred. As it
is clearly stated in the article these two type E dissections evolved
toward complete artery occlusion during the procedure and how
they caused an acute myocardial infarction immediately after the
procedure. Because the study reported the results of nonocclusive
unstented dissections, they were excluded from the analysis at the
beginning.
As far as the second point is concerned, we have acknowledged
the higher prevalence of lesions A and B in the unstented group,
but this limitation derives from the later stage in which the stented
patients were assessed, when the easy availability of stenting
allowed higher inflation pressures. However, although unstented
patients had a higher prevalence of dissections grades A and B
(namely 85% vs. 56% at 24 h), the restenosis rate for stented and
unstented patients was similar for each dissection grade (p 5 NS).
What we would like to stress in our study is that in this stenting
era, where there is a growing and widespread use of these devices
(2), the “minor” dissections (type A and B), most frequently
occurring during PTCA, are associated with a very low risk of
complications and restenosis, suggesting a more conservative
approach.
Finally, Dr. Alfonso states that “the large lumen diameter of the
dissected segments indicates that the dissection image was fully
included into the lumen measurements.” However, as clearly
shown in Table 1 of our article, the mean lumen diameter
post-PTCA in dissected vessels was not 3.23 6 0.65 mm but
3.11 6 0.89 mm, a lower value than that of the mean reference
artery diameter pre-PTCA (3.18 6 0.7 mm) in the same vessels.
We do agree that the methodology of quantitative coronary
angiography is technically demanding, especially for the analysis of
dissected segments. Therefore, we are promoting in our Institute
new and different tools for quantitative analysis, such as intracoro-
nary ultrasound (IVUS), coronary Doppler evaluation, and myo-
cardial fractional flow-reserve measurement.
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Coenzyme Q10 as an Adjunctive Therapy
in Patients With Congestive Heart Failure
Lack of effect from treatment with coenzyme Q10 in congestive
heart failure is not an objective title or conclusion for the study by
Watson et al. (1) in which the main limitation obviously is their
sample size and its lack of study patients. Even so, the investigators
state in their introduction that previous studies with coenzyme
Q10 “lack credibility because of small sample sizes, lack of
controls, etc.”
The majority of the 27 study patients, who were not classified
according to the New York Heart Association (NYHA), were
seemingly at late-stage disease (mean length of symptoms 3.4
years). Mean patient age was 55 years, which is compatible with
predominantly ischemic origin. This was also recently confirmed at
an International Conference in Sydney, Australia—“Oxidative
Pathways in Health and Disease”—in a lecture by one of the
co-authors, Nicholas Bett (2). However, according to the Watson
et al. (1) study, in the Patients’ Demographics in Table 1, 77% of
the patients were listed as having dilated cardiomyopathy. This is
a patient clientele that is, at least partially, prone to respond either
spontaneously or to medical intervention with subsequent im-
provement of myocardial function.
Conversely, it is well-known that changes—and not least
improvements—in echocardiographic parameters of left ventricu-
lar (LV) function are minimal in late-stage disease, especially in
heart failure due to ischemic heart disease. This is why the
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calculated number of patients necessary (n 5 17) in this cross-over
trial seems highly underestimated.
In a nearly threefold larger trial of 79 patients from Scandinavia,
the same double-blind, cross-over design was used over two
periods of three months on coenzyme Q10 100 mg/day or placebo.
The beneficial results of this study were presented initially at The
American College of Cardiology Meeting in 1992 (JACC 1992;
19:216A, abstract 774–6) and later published in the Journal of
Cardiac Failure (3). Watson et al. (1) have not included this trial in
their reference list.
In the Scandinavian Multicenter Study, a balanced randomiza-
tion was used with respect to the diagnosis of ischemic versus
nonischemic disease and the treatment with or without an
angiotensin-converting enzyme inhibitor. There was a slight im-
provement on LV ejection fraction at volume load based on the
results from the MUGA scans (p 5 0.025). Maximal exercise
capacity increased slightly but significantly (p 5 0.016) and
coenzyme Q10 mediated a significant decrease in the scoring for
dyspnea (p 5 0.007) and leg fatigue (p 5 0.04) at end-exercise
(using the Borg-scale). According to the scoring from the Quality
of Life Questionnaire, the total score (p 5 0.016), the physical
activity level (p 5 0.048) and the life satisfaction (p 5 0.016)
increased significantly during the coenzyme Q10 period.
During the last 15 years, only 2 of 12 double-blind heart-failure
trials have been “neutral” (i.e., without positive effect or side
effects), whereas the remaining 10 studies have been positive and
statistically significant with respect to improvement in clinical and
or hemodynamic parameters (4). In Watson and colleagues’
“neutral study,” adequate methods to assess myocardial function
were used, but obviously the trial was insufficiently powerful to
confirm or reject the hypothesized increase in LV function.
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REPLY
We thank Dr. Mortensen for his interest in our study (1). We
assure him that the data we reported on patient demographics are
correct—that over three-quarters of our patients suffered from
dilated cardiomyopathy while the remainder had coronary heart
disease. When we stated that we would require 17 patients in order
to demonstrate an increase in left ventricular ejection fraction from
25% to 30% with a standard deviation (SD) of 5% using 95%
confidence intervals (CI) with a power of 80% (1), we did no more
than calculate the probability that our failure to show such as
change (a negative study) would reflect a true lack of effort.
The design of the Scandinavian study to which Dr. Mortensen
refers (2) was very similar to that of our trial. Despite having nearly
three times as many patients, it also failed to show any significant
difference (p , 0.05) in this primary end point. The study reported
by Permanetter et al. (3) also failed to show any therapeutic effect
of coenzyme Q 10. Meta-analysis of clinical trials of coenzyme
Q 10 treatment of congestive heart failure might be seen as
encouraging but cannot be taken as any more than an argument for
more blinded control studies (4,5).
We agree with Dr. Mortensen that if agents such as coenzyme
Q 10 are to be helpful, this would more likely be demonstrable
early in the course of heart failure. Unfortunately, success in
treating chronic failure with angiotensin-converting enzyme inhib-
itors (6), beta-adrenergic blockers (7), and spironolactone (8)
means that it has become increasingly difficult to recruit patients
for trials of unproven agents until they have been stabilized on
what must now be regarded as standard therapy.
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